Thermo Fisher Scientific Completes Acquisition of One Lambda
Complete the form below to unlock access to ALL audio articles.
Based in Canoga Park, Calif., One Lambda has approximately 320 employees and had 2011 revenue of $182 million.
“We are pleased to welcome One Lambda to our team and significantly increase our access to the attractive transplant diagnostics market,” said Marc N. Casper, president and chief executive officer of Thermo Fisher Scientific. “One Lambda’s tests for tissue typing and antibody detection complement our existing immunosuppressant assays, allowing us to offer a broad menu of tests across the transplant-testing workflow. We are excited about this combination and the opportunities it presents to ultimately improve the lives of transplant patients.”
Thermo Fisher reiterated its expectation that the One Lambda transaction will be accretive to 2012 adjusted earnings per share (EPS) and that it will add $0.09 to $0.11 to the company’s 2013 adjusted EPS results. Based upon the timing of the close, the transaction will have an immaterial impact on Thermo Fisher’s third quarter adjusted EPS. The company will provide updated guidance for 2012 when it reports its third quarter 2012 financial results.
